BNP Paribas Financial Markets Sells 17,541 Shares of Quanterix Co. (NASDAQ:QTRX)

BNP Paribas Financial Markets reduced its holdings in Quanterix Co. (NASDAQ:QTRX) by 69.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,577 shares of the company’s stock after selling 17,541 shares during the period. BNP Paribas Financial Markets’ holdings in Quanterix were worth $98,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. nVerses Capital LLC acquired a new stake in shares of Quanterix in the third quarter worth $60,000. Canada Pension Plan Investment Board acquired a new stake in Quanterix in the 2nd quarter worth $140,000. SG Americas Securities LLC bought a new position in shares of Quanterix during the 3rd quarter worth about $139,000. Hsbc Holdings PLC raised its position in shares of Quanterix by 34.7% during the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock valued at $164,000 after buying an additional 3,279 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Quanterix during the third quarter worth about $170,000. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, TD Cowen raised their price objective on Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a research report on Wednesday, November 13th.

Quanterix Stock Performance

Shares of Quanterix stock opened at $10.33 on Thursday. The firm has a market cap of $396.46 million, a P/E ratio of -9.84 and a beta of 1.30. The firm’s 50-day simple moving average is $12.47 and its 200-day simple moving average is $13.16. Quanterix Co. has a twelve month low of $9.99 and a twelve month high of $29.70.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.